Physician profile
Brook A Gram
NPI 1740321090
$52,398.66
in general payments reported to CMS, 2019-2025
36 companies · $1,390 in 2025
The $1,390 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12K · 2022: $15K · 2023: $19K · 2024: $5,847 · 2025: $1,390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Food and Beverage: $4,734 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,978.06 |
| Food and Beverage | $4,734.05 |
| Education | $108.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $38,209.50 | 2021-2024 | Minimed 780g, Minimed 770g |
| Insulet Corporation | $5,633.94 | 2022 | |
| Abbvie INC. | $1,806.10 | 2021-2025 | |
| Lilly USA, LLC | $1,076.77 | 2021-2025 | Jardiance, Mounjaro, Lyumjev |
| Novo Nordisk INC | $700.25 | 2021-2023 | Rybelsus, Ozempic, Wegovy |
| Corcept Therapeutics | $566.12 | 2021-2023 | Korlym |
| Amgen INC. | $540.65 | 2021-2025 | Otezla, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $416.00 | 2022-2023 | |
| Amarin Pharma, INC. | $388.71 | 2021-2023 | |
| Janssen Biotech, INC. | $339.95 | 2025 | Tremfya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $328.59 | 2021-2024 | Tradjenta, Jardiance, Spevigo |
| Ucb, INC. | $294.60 | 2021-2025 | Bimzelx |
| Genzyme Corporation | $271.01 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $263.92 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $228.33 | 2024-2025 | Sotyktu |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brook Gram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.